4 results
The purpose of this current study is to evaluate the efficacy and safety of the 3-day oral aprepitant regimen when administered concomitantly with ondansetron, with or without dexamethasone, in pediatric patients, from 6 months to 17 years of age,…
Part 1: The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to…
To investigate the influence of aprepitant on the exposure to etoposide in TC patients treated with (B)EP.
Primary• To evaluate the safety and tolerability of AMG 910 in adult subjects. • To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Secondary• To characterize the PK of AMG 910• To evaluate preliminary anti-tumor…